MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback